Disclosed herein is a biomaterial and a method of use thereof for treating a condition. A biomaterial of the disclosure can be, for example, a surgical article. Implantation of a biomaterial disclosed herein into a subject can treat, for example, cancer.

The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device. The pre-filled syringe comprises a container and a needle. The container is filled with a pharmaceutical composition comprising epinephrine, a buffer, and water. The buffer is configured to buffer in a pH range between 3 and 4. The needle is adhered to the container by means of a urethane acrylate or urethane methacrylate acrylic light cure adhesive, which is configured to provide a pull out resistance of the needle relative to the container which is between 30 N to 100 N, preferably between 50 N to 70 N, more preferably greater than 60 N after 90 days exposure to the pharmaceutical composition at 40 C. and 75% relative humidity (RH). In an example, the pharmaceutical composition is for the treatment of an anaphylactic event.

The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device. The pre-filled syringe comprises a container and a needle. The container is filled with a pharmaceutical composition comprising epinephrine, a buffer, and water. The buffer is configured to buffer in a pH range between 3 and 4. The needle is adhered to the container by means of a urethane acrylate or urethane methacrylate acrylic light cure adhesive, which is configured to provide a pull out resistance of the needle relative to the container which is between 30 N to 100 N, preferably between 50 N to 70 N, more preferably greater than 60 N after 90 days exposure to the pharmaceutical composition at 40 C. and 75% relative humidity (RH). In an example, the pharmaceutical composition is for the treatment of an anaphylactic event.

An intraoral imaging apparatus for tomosynthesis imaging has an x-ray source having a primary collimator that defines boundaries of a radiation field. A transport apparatus translates the x ray source along a path for tomographic imaging. An intraoral x-ray detector defines an imaging area for the radiation field. A positioning apparatus correlates the position of the intraoral detector to the position of a secondary collimator. One or more radio-opaque markers provided on a detector attachment is coupled to the detector, the one or more markers configured to condition acquired x-ray images to relate the spatial position of the intraoral x-ray detector to the x-ray source position, wherein the one or more markers are disposed within the defined imaging area. A control logic processor accepts image data from the detector and determines the relative location of the source with respect to the detector according to detected marker position.

A shunt for draining ocular fluid of one embodiment includes a tubular body formed of a mesh material including bioactive glass fiber and collagen, the tubular body including an implantation member and a conduit through the implantation member. The implantation member and the conduit are formed integrally. Other embodiments are also contemplated.

A syringe containing a compressible porous matrix, which compressible porous matrix has in it a pharmaceutical in a soluble glass, Methods of producing and using the syringe, and compressible porous matrix inserts for insertion into a syringe barrel are also provided.

The implantable medical device comprises an elongated composite tubular body comprising a tubular part made of a biocompatible and RF wave permeable dielectric material and a tubular part made of a biocompatible metallic material. The dielectric tubular part and the metallic tubular part are arranged end-to-end at their interface against the respective planar end faces thereof, without being fit into each other. The interface comprises a planar brazing sealing to each other the two opposite respective planar end faces of the dielectric material tubular part and of the metallic material tubular part. With a dielectric material that is a high-purity alumina ceramic and a metallic material that is titanium, the brazing is obtained by gold brazing on a TiNb primer metallization layer deposited on the planar end face of the dielectric material tubular part.

To provide a medical device, whereby the non-specific absorption amount is reduced, its durability is excellent and eluents from the surface layer are reduced. The medical device comprises a device substrate and a surface layer provided on at least part of the surface of the device substrate in contact with water, wherein at least part of the surface of the device substrate is made of an inorganic material, the surface layer is made of a cured product of a compound having a biocompatible group and an alkoxysilyl group, the content of the biocompatible group in the compound is from 25 to 83% by mass, and the content of the alkoxysilyl group is from 2 to 70% by mass.

Methods for improving the antibacterial characteristics of biomedical implants and related implants manufactured according to such methods. In some implementations, a biomedical implant comprising a silicon nitride ceramic material may be subjected to a surface roughening treatment so as to increase a surface roughness of at least a portion of the biomedical implant to a roughness profile having an arithmetic average of at least about 500 nm Ra. In some implementations, a coating may be applied to a biomedical implant. Such a coating may comprise a silicon nitride ceramic material, and may be applied instead of, or in addition to, the surface roughening treatment process.

The present invention provides an orthopedic implant comprising a continuous reinforced composite filament in a freely predetermined fiber orientation in multiple continuous successive layers, wherein the continuous reinforced composite filament comprises a bioabsorbable polymer matrix and a continuous bioabsorbable reinforcing fiber or fiber bundle, and whereby the continuous bioabsorbable reinforcing fiber or fiber bundle of consecutive layers at least partly intermingles and/or intertwines forming a three dimensionally interlocked continuous fiber structure.